Science Explorer Back to mapMap
Discussion
Company · Siena · Italy

Philogen (Italy)

philogen.comROR OpenAlex
Research works
43
▲ 286% vs 2018-21
Citations
1.1k
25.9 per fractional work
Top-10% rate
18.9%
all institutions 10.0%
Open access
51%
world 40%
International
79%
world 18%
Philogen (Italy)

Not ranked overall: Philogen (Italy) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Philogen (Italy) work in?

In 2022-now, 62% of research at Philogen (Italy) is in Health Sciences, 26% in Life Sciences. Its largest fields are Medicine (62%), Biochemistry, Genetics and Molecular Biology (19%), Immunology and Microbiology (6%). It does 2.0× the world's share of Health Sciences.

Health Sciences: 13 fractional works · 62.4% of its workMedicine: 13 fractional works · 62.0% of its workOncology: 5 fractional works · 24.7% of its workRadiology, Nuclear Medicine and Imaging: 4 fractional works · 21.4% of its workGenetics: 1 fractional works · 4.1% of its workPulmonary and Respiratory Medicine: 1 fractional works · 2.8% of its workImmunology and Allergy: 1 fractional works · 2.6% of its workSurgery: 0 fractional works · 2.0% of its workEpidemiology: 0 fractional works · 2.0% of its workNeurology: 0 fractional works · 1.3% of its workPathology and Forensic Medicine: 0 fractional works · 0.4% of its workPsychiatry and Mental health: 0 fractional works · 0.4% of its workHematology: 0 fractional works · 0.3% of its workVeterinary: 0 fractional works · 0.4% of its workSmall Animals: 0 fractional works · 0.4% of its workLife Sciences: 6 fractional works · 26.4% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 18.7% of its workMolecular Biology: 3 fractional works · 12.5% of its workBiotechnology: 1 fractional works · 2.8% of its workCell Biology: 0 fractional works · 1.1% of its workGenetics: 0 fractional works · 1.0% of its workCancer Research: 0 fractional works · 1.0% of its workStructural Biology: 0 fractional works · 0.4% of its workImmunology and Microbiology: 1 fractional works · 6.4% of its workImmunology: 1 fractional works · 6.4% of its workNeuroscience: 0 fractional works · 1.4% of its workCellular and Molecular Neuroscience: 0 fractional works · 1.4% of its workPhysical Sciences: 2 fractional works · 11.2% of its workChemistry: 1 fractional works · 5.6% of its workOrganic Chemistry: 1 fractional works · 3.9% of its workSpectroscopy: 0 fractional works · 1.4% of its workInorganic Chemistry: 0 fractional works · 0.4% of its workEngineering: 1 fractional works · 2.9% of its workBiomedical Engineering: 1 fractional works · 2.9% of its workComputer Science: 0 fractional works · 1.2% of its workComputational Theory and Mathematics: 0 fractional works · 1.2% of its workMaterials Science: 0 fractional works · 1.2% of its workBiomaterials: 0 fractional works · 1.2% of its workEnvironmental Science: 0 fractional works · 0.3% of its workEcology: 0 fractional works · 0.3% of its workALL ITS WORKPhilogen (Italy)21fractional works, 2022-now
Life Sciences26%Physical Sciences11%Health Sciences62%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 10 fields, with their numbers
    1. Medicine1362.0%
    2. Veterinary00.4%
    1. Biochemistry, Genetics and Molecular Biology418.7%
    2. Immunology and Microbiology16.4%
    3. Neuroscience01.4%
    1. Chemistry15.6%
    2. Engineering12.9%
    3. Computer Science01.2%
    4. Materials Science01.2%
    5. Environmental Science00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 3.50× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 6.35× its world share, 1 worksImmunology and Micro…Neuroscience: 0.85× its world share, 0 worksNeuroscienceChemistry: 3.59× its world share, 1 worksChemistryComputer Science: 0.15× its world share, 0 worksComputer ScienceEngineering: 0.19× its world share, 1 worksEngineeringEnvironmental Science: 0.05× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.34× its world share, 0 worksMaterials ScienceMedicine: 3.23× its world share, 13 worksMedicineVeterinary: 2.94× its world share, 0 worksVeterinary1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.3×. Every wedge is a field page.

All 10 fields, with their numbers
  1. Immunology and Microbiology6.35×1 works
  2. Chemistry3.59×1 works
  3. Biochemistry, Genetics and Molecular Biology3.50×4 works
  4. Medicine3.23×13 works
  5. Veterinary2.94×0 works
  6. Neuroscience0.85×0 works
  7. Materials Science0.34×0 works
  8. Engineering0.19×1 works
  9. Computer Science0.15×0 works
  10. Environmental Science0.05×0 works

Who are the top researchers at Philogen (Italy)?

Ranked on the quality score, Leonardo Giovannoni lead among researchers whose main affiliation is Philogen (Italy).

  1. 1 Leonardo Giovannoni Italy · #310,386 worldwide 2.6k citations · 86 works
All ranked researchers at Philogen (Italy)

What are the most cited papers from Philogen (Italy)?

The most cited paper from Philogen (Italy) is "Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin" (Laura Borsi, Enrica Balza, Marco Bestagno et al., 2002), with 360 citations. Next come "DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges" (329) and "Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer." (294).

Most cited papers
#PaperReleasedCitations
1 Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin Laura Borsi, Enrica Balza, Marco Bestagno et al. · International Journal of Cancer Open access 25 Sep 2002 360
2 DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges Adrián Gironda-Martínez, Etienne J. Donckèle, Florent Samain et al. · ACS Pharmacology & Translational Science Open access 14 Jun 2021 329
3 Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Monica Santimaria, Giovanni Moscatelli, Giuseppe Viale et al. · PubMed Feb 2003 294
4 The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma Manfred Johannsen et al. · European Journal of Cancer 25 Aug 2010 188
5 Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study Riccardo Danielli, Roberto Patuzzo, Anna Maria Di Giacomo et al. · Cancer Immunology Immunotherapy Open access 13 May 2015 183
All 60 most cited papers, with filters and sorting

Which keywords describe research at Philogen (Italy)?

By fractional works in 2022-now, weighted toward what it does more of than the world: PET Imaging, Immunotherapy, Angiogenesis, Tumor Microenvironment, Cancer Therapy, Fibroblast Activation Protein, Immunosuppression and Cancer Treatment.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 26 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 26 words, with their numbers
  1. PET Imaging5▲ 145×3 topics
  2. Immunotherapy4▲ 28×9 topics
  3. Angiogenesis4▲ 57×5 topics
  4. Cancer Therapy3▲ 29×5 topics
  5. Tumor Microenvironment3▲ 37×3 topics
  6. Fibroblast Activation Protein3▲ 332×1 topic
  7. Immunosuppression3▲ 157×1 topic
  8. Cancer Treatment2▲ 46×2 topics
  9. Glycosylation2▲ 90×2 topics
  10. Radiopharmaceuticals2▲ 345×1 topic
  11. Targeted Therapy2▲ 44×1 topic
  12. Cancer Immunotherapy2▲ 60×2 topics
  13. Tumor Regression2▲ 80×2 topics
  14. Antibody Engineering2▲ 154×1 topic
  15. Fc Receptors2▲ 154×1 topic
  16. Monoclonal Antibodies2▲ 97×2 topics
  17. Therapeutic Antibodies2▲ 124×2 topics
  18. Cancer2▲ 5.9×6 topics
  19. Drug Discovery2▲ 36×3 topics
  20. Lymphoma1▲ 41×2 topics
  21. Tumor Targeting1▲ 37×3 topics
  22. CAR T Cells1▲ 84×1 topic
  23. Chimeric Antigen Receptor1▲ 84×1 topic
  24. Inflammation1▲ 2.5×6 topics
  25. Foldamers1▲ 161×1 topic
  26. Peptide Synthesis1▲ 161×1 topic

Which research topics does Philogen (Italy) publish most on?

By volume in 2022-now: Peptidase Inhibition and Analysis, Radiopharmaceutical Chemistry and Applications, Monoclonal and Polyclonal Antibodies Research and CAR-T cell therapy research.

Peptidase Inhibition and…3Peptidase Inhibition and Analysis: 3 fractional worksRadiopharmaceutical Chemistry and Applications: 2 fractional worksMonoclonal and Polyclonal Antibodies Research: 2 fractional worksCAR-T cell therapy research: 1 fractional worksChemical Synthesis and Analysis: 1 fractional worksGlioma Diagnosis and Tre…1Glioma Diagnosis and Treatment: 1 fractional worksImmunotherapy and Immune Responses: 1 fractional worksNanoplatforms for cancer theranostics: 1 fractional worksCancer Research and Treatments: 1 fractional worksClick Chemistry and Applications: 1 fractional works
OncologyRadiology, Nuclear Medicine and ImagingMolecular BiologyGenetics4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Peptidase Inhibition and Analysis Oncology 3 works
  2. 2 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 2 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
  4. 4 CAR-T cell therapy research Oncology 1 works
  5. 5 Chemical Synthesis and Analysis Molecular Biology 1 works
  6. 6 Glioma Diagnosis and Treatment Genetics 1 works
  7. 7 Immunotherapy and Immune Responses Immunology 1 works
  8. 8 Nanoplatforms for cancer theranostics Biomedical Engineering 1 works
  9. 9 Cancer Research and Treatments Biotechnology 1 works
  10. 10 Click Chemistry and Applications Organic Chemistry 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available50.9%not open49.1%

World: 40% of research is openly available.

with international co-authors79.1%domestic only20.9%

World: 18% is written across borders.

How has Philogen (Italy)'s research output changed?

Output in 2022-2025 was 286% higher than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Philogen (Italy) as a percentage of every work published that year, 0.00011% in 2024.

still counting0.000050%0.00010%0.00015%Philogen (Italy)0.000060% in 2025200020102020

Fractional works of Philogen (Italy) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Siena

All research institutions in Siena

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Philogen (Italy). Posts are plain text and can be reported.